Genomics Inform.
2016 Dec;14(4):205-210. 10.5808/GI.2016.14.4.205.
Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP
- Affiliations
-
- 1Department of System Cancer Science, Graduate School of Cancer Science and Policy, Goyang 10408, Korea. ksy@ncc.re.kr
- 2Center for Breast Cancer, National Cancer Center, Goyang 10408, Korea.
- 3College of Veterinary Medicine, Konkuk University, Seoul 05029, Korea.
- 4Biometric Research Branch, Division of Cancer Epidemiology and Prevention, National Cancer Center, Goyang 10408, Korea.
- 5Center for Hematologic Malignancy, National Cancer Center, Goyang 10408, Korea.
- 6Department of Laboratory Medicine, Center for Diagnostic Oncology, Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea.
- KMID: 2366437
- DOI: http://doi.org/10.5808/GI.2016.14.4.205
Abstract
- Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms in IL10 with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest that IL10 polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP.
MeSH Terms
-
Alleles
B-Lymphocytes*
Cell Lineage
Cyclophosphamide
Disease-Free Survival
Doxorubicin
Humans
Interleukin-10*
Introns
Korea
Lymphoma, B-Cell*
Lymphoma, Mantle-Cell
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Male
Models, Genetic
Polymorphism, Single Nucleotide
Prednisone
Prognosis*
Rituximab
RNA, Messenger
Vincristine
Cyclophosphamide
Doxorubicin
Interleukin-10
Prednisone
RNA, Messenger
Rituximab
Vincristine
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth
- Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck diffuse large B-cell lymphoma: a single institutional experience
- Angiocentric T cell Lymphoma associated with Epstein-Barr Virus
- Rituximab Plus CHOP for the Treatment of Primary Mediastinal Large B Cell Lymphoma in a Pregnant Woman
- Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
